Review
Nature Reviews Drug Discovery 2, 903-915 (November 2003) | doi:10.1038/nrd1224
New targets for allergic rhinitis — a disease of civilization
Stephen T. Holgate1 & David Broide2 About the authors
Abstract
Allergic rhinitis is an inflammatory disorder of the nasal mucosa, mediated by TH2 lymphocytes, which is linked to atopy and whose prevalence is increasing in association with a Western lifestyle. The production of allergen-specific IgE, activation of mucosal mast cells and the recruitment and activation of effector leukocytes provides potential therapeutic targets, including selective inhibition of cytokines, adhesion molecules and signalling pathways. Blockade of IgE, using monoclonal antibodies and vaccine strategies, is a new approach for interrupting the allergic cascade, whereas the use of recombinant mutated allergens, peptides and DNA oligonucleotides will lead to improved efficacy and reduced side effects of immunotherapy to induce tolerance.
- View At a Glance
Author affiliations
- RIIR Division, School of Medicine, University of Southampton, Mail point 810, Level D, Centre Block Southampton General Hospital, Southampton SO16 6YD, UK.
- Department of Medicine, University of California San Diego, Basic Science Building, 9500 Gilman Drive, La Jolla, California 92093 -0635, USA.
Correspondence to: Stephen T. Holgate1 Email: sth@soton.ac.uk
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated REFERENCE NEWS AND VIEWS RESEARCH |
